Proleukin in Combination With Rituxan in Patients With Intermediate and High-Grade Non-Hodgkin's Lymphoma.
NCT ID: NCT00045864
Last Updated: 2006-02-06
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
INTERVENTIONAL
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
TREATMENT
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Recombinant Human Interleukin-2 and Rituximab
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion:
* Clinically significant cardiac dysfunction, or a history of myocardial infarction or heart failure within 6 months of first study treatment
* Clinically significant pulmonary dysfunction.
* Liver disease (note hepatitis C seropositive subjects may be enrolled if they have no active disease as demonstrated by undetectable HCV viral loads, biopsy showing no active disease, and/or history of normal transaminases on at least three different dates within one year of first study treatment).
* Symptomatic thyroid disease requiring medical intervention other than replacement treatment for hypothyroidism.
* History of autoimmune disease.
* History of positive serology for human immunodeficiency virus (HIV).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Chiron Corporation
INDUSTRY
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
ACRC/Arizona Clinical Research Center, Inc.
Tucson, Arizona, United States
Hoag Cancer Center
Newport Beach, California, United States
UC Davis Cancer Center
Sacramento, California, United States
John Wayne Cancer Institute
Santa Monica, California, United States
Stanford University Medical Center
Stanford, California, United States
California Cancer Medical Center
West Covina, California, United States
Georgetown University Medical Center, Lombardi Cancer Center
Washington D.C., District of Columbia, United States
Washington Cancer Institute
Washington D.C., District of Columbia, United States
Division of Hematology/Oncology, University of Miami School of Medicine
Miami, Florida, United States
Northwestern University, Feinberg School of Medicine
Chicago, Illinois, United States
Rush Cancer Institute
Chicago, Illinois, United States
Oncology Specialists, S.C.
Park Ridge, Illinois, United States
Cancer Care Center
Bloomington, Indiana, United States
Consultants in Blood Disorders and Cancer
Louisville, Kentucky, United States
Louisiana Health Sciences Center, Department of Medicine, Hematology/Oncology
Shreveport, Louisiana, United States
Kansas City Oncology and Hematology Group
Kansas City, Missouri, United States
Arch Medical Group, LLC
St Louis, Missouri, United States
Dartmouth-Hitchcock-Medical Center
Lebanon, New Hampshire, United States
Memorial Sloan Kettering Cancer Center
New York, New York, United States
Our Lady of Mercy Medical Center, Comprehensive Cancer Center
The Bronx, New York, United States
East Carolina University School of Medicine/ Division of Hematology/Oncology
Greenville, North Carolina, United States
Roger Maris Health System
Fargo, North Dakota, United States
Gabrail Cancer Center
Canton, Ohio, United States
Oncology Hematology Care Inc.
Cincinnati, Ohio, United States
The Cleveland Clinic Foundation
Cleveland, Ohio, United States
Hematology /Oncology Consultants Inc.
Columbus, Ohio, United States
Oregon Heath and Science University
Portland, Oregon, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
Cancer Centers of the Carolinas
Greenville, South Carolina, United States
Germantown Cancer Center
Germantown, Tennessee, United States
Vanderbilt University Medical Center
Nashville, Tennessee, United States
Cancer Specialists of South Texas, P.A.
Corpus Christi, Texas, United States
Virginia Cancer Institute
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
IL2NHL05
Identifier Type: -
Identifier Source: org_study_id